Sign in
Taking people in United StatesPhase 2

Pyridostigmine compared with placebo for postural tachycardia syndrome

Tests pyridostigmine against a placebo in people with postural tachycardia syndrome.

Key facts

Who runs it
Mayo Clinic
Where
Rochester, United StatesSee the site
Trial code
Registry title
A Study of Pyridostigmine in Postural Tachycardia Syndrome
Status
Recruiting
Phase
Phase 2
People taking part
50 people, planned
Started
Oct 2006
Expected to end
Feb 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • pyridostigmine
  • Placebo
Record updated
5 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with postural tachycardia syndrome (POTS). It compares pyridostigmine with a placebo (dummy pill) over 3 days.

Age
15 Years to 55 Years
Sex
All sexes can join
Disease stage
POTS diagnosis: heart rate rises by 30 bpm or more within 5 minutes of a head-up tilt test, plus symptoms when standing, such as weakness, lightheadedness, blurred vision, nausea, palpitations or trouble thinking. Both must be present.
Earlier treatment
People who were treated with pyridostigmine for POTS before cannot join. No pyridostigmine in the past month.

Main reasons for not taking part

  • Pregnant or breastfeeding women
  • Failure of other organs, or a body-wide illness that could affect the nervous control of the body or the ability to take part
  • Underactive or overactive thyroid
  • Clinically significant heart artery disease
  • Medicines that could interfere with the nervous system tests

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Diagnosis of postural tachycardia syndrome using the following criteria:
  • Orthostatic heart rate increment greater than or equal to 30 beats per minute (bpm) within 5 minutes of head-up tilt
  • Symptoms of orthostatic intolerance. These include weakness, lightheadedness, blurred vision, nausea, palpitations, and difficulty with concentration and thinking; Both criteria must be fulfilled

Who cannot take part

  • Medications that could interfere with autonomic testing
  • Previous treatment with pyridostigmine for POTS. Patients must not have taken pyridostigmine in the past month
  • Presence of failure of other organ systems or systemic illness that could affect autonomic function or the patient's ability to cooperate with the study
  • Clinically significant coronary artery disease
  • Pregnant or lactating women
  • Hypothyroidism or hyperthyroidism

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 15 and 55 years old?

Where in United States

  • Mayo ClinicRochester, United StatesContact: Toni GehrkingTaking people

About the trial

What the trial wants to find out

This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.

The 2 groups in the trial

  • pyridostigmineExisting treatment, for comparison

    Active study drug

  • PlaceboPlacebo, for comparison

    Control

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Double-Blind, Placebo-Controlled Study of Pyridostigmine in Postural Tachycardia Syndrome
Plain-language title
Pyridostigmine compared with placebo for postural tachycardia syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT00409435, who can take part
Record updated
5 March 2026